Surrozen, Inc. reported $12M of revenue over the trailing twelve months, −8.8% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $12M (to Q2 2026). Net income: −$332M, trailing twelve months to Q2 2026. Free cash flow: −$35M, trailing twelve months to Q2 2026. Operating margin: −979%, trailing twelve months to Q2 2026.

SRZNSurrozen, Inc.

Healthcare

$28.01+104% 1Y

$28.01

$11.8052 weeks$34.13

SRZN as reported

Surrozen, Inc. reported $12M of revenue over the trailing twelve months, −8.8% on the year before. 8 reported series are charted on this page, each one as filed.

$12M

Revenue, trailing twelve months · to Q2 2026 · −8.8% against the twelve months before

Net income: −$332M
Net income · +1889% year on year · trailing twelve months to Q2 2026
Free cash flow: −$35M
Free cash flow · +87% year on year · trailing twelve months to Q2 2026
Operating margin: −979%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SRZN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$12M	−8.8%	Q2 2026
Net income	−$332M	+1889%	Q2 2026
EPS	−$44.30	+207%	Q2 2026
Operating margin	−979%	n/a	Q2 2026
Net margin	−10881%	n/a	Q2 2026
ROE	193%	n/a	Q2 2026
ROA	−227%	n/a	Q2 2026
Free cash flow	−$35M	+87%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.